Goldman Sachs Downgrades Allergen (AGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Downgrades Allergen (AGN) to Neutral
June 24, 2013 12:38 PM EDTCiti downgraded Allergen (NYSE: AGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $92.70 yesterday, with a 52 week range of $81.28-$116.45.... More
SunTrust Robinson Humphrey Downgrades Allergen (AGN) to Neutral
June 24, 2013 8:10 AM EDTSunTrust Robinson Humphrey downgraded Allergen (NYSE: AGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $92.70 yesterday, with a 52 week range of $81.28-$116.45.... More
Deutsche Bank Downgrades Allergen (AGN) to Hold; Sees 'Overhang' from Generic Restasis
June 24, 2013 7:10 AM EDTDeutsche Bank downgraded Allergen (NYSE: AGN) from Buy to Hold with a price target of $98.00 (from $113.00) after the FDA issued draft guidance for a non-clinical study pathway for generics to Restasis, the company's 2nd largest drug (~14% of revs) with 2015E sales of $1B+.
... More
Leerink Swann Downgrades Allergen (AGN) to Market Perform on Prospect of Restasis Generics
June 24, 2013 7:07 AM EDTLeerink Swann downgraded Allergen (NYSE: AGN) from Outperform to Market Perform with a price target of $102.00 (from $113-$114).
"We are downgrading AGN from Outperform to Market Perform following the release of surprisingly straightforward draft guidance from the FDA for Restasis generics (dry eye)," analyst... More
Goldman Sachs Upgrades Forest Laboratories (FRX) to Buy; Potential for Strategic Options
June 21, 2013 7:31 AM EDTGoldman Sachs upgraded Forest Laboratories (NYSE: FRX) from Neutral to Buy with a price target of $50.00 (from $40.00) citing increased potential for strategic options.
In its upgrade report analyst Jami Rubin notes... More
